Clinical trial NCT05494788: Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot)
Official title: Impact of CardiolRxTM on Recurrent Pericarditis An Open Label Pilot Study (MAvERIC-Pilot Study)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Recurrent Pericarditis
Lead sponsor: Cardiol Therapeutics Inc.
Sponsor class: INDUSTRY
First posted: 2022-08-10
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Open label
Primary purpose: TREATMENT

Brief summary: Patients with recurrent pericarditis who are refractory or intolerant to current therapeutic management options or who require long-term administration of corticosteroids to control their disease are particularly challenging to manage. The pathogenesis of pericarditis involves the activation of the inflammasome. CardiolRxTM (a pure cannabidiol \[CBD\] solution) is known to have anti-inflammatory properties, including modulation of inflammasome signaling. This pilot study is to assess the tolerance and safety of CardiolRxTM during the resolution of pericarditis symptoms, assess improvement in objective measures of disease, and during the extension period, assess the feasibility of weaning concomitant background therapy including corticosteroids while taking CardiolRxTM.

Detailed description: Multi-center, open label Pilot Study. Patients who present with recurrent pericarditis will be screened and informed consent obtained.

Baseline assessments include the following: Clinical assessment, including vital signs, highest NRS pain score within the past 7 days of Day 1, 12-lead ECG; C-SSRS as well as hematology and blood chemistry and a pregnancy test for women with child-bearing potential.

Concomitant medications are recorded and any (S)AEs after informed consent has been obtained.

Study treatment will be initiated in the evening of Day 1, after all baseline assessments are completed.

Oral administration is as follows:

* Initial starting dose (Day 1 p.m. dose to Day 3 a.m. dose):

  5 mg/kg of body weight CardiolRxTM
* Day 3 p.m. dose to Day 10 a.m. dose: 7.5 mg/kg of body weight CardiolRxTM b.i.d.
* Day 10 p.m. dose to end of treatment period: 10.0 mg/kg of body weight CardiolRxTM b.i.d.

If the next higher dose after each study drug increase is not tolerated, the dose will be reduced to the previous tolerated dose.

Unless contraindicated in the opinion of the investigator, after 8 weeks of treatment, patients will enter an 18-week extension period (EP), in which they continue study treatment while their concomitant medications will be weaned.

Follow-up Procedures Every visit (before the next dose increase) the patient will be re-evaluated. This includes ECG monitoring at approximately 5 hours post-morning dose (Tmax) to surveil for deleterious effects on ECG intervals (particularly the QTc interval) and rhythm.

Drug titration will be dependent on investigator or designate interrogation of the ECGs and the absence of new, clinically significant abnormalities on those ECGs.

Vital signs, concurrent medication and (S)AEs will be recorded at all visits. Blood chemistry including liver function tests, hematology as well as INR assessments will be carried out at selected visits.

Final efficacy assessments will take place after 26 weeks of study treatment and include a clinical assessment, vital signs, pain score NRS, a 12-lead ECG, the C-SSRS, as well as laboratory assessments.

For patients who do not enter the EP, Final assessments will be done after 8 weeks.

Eligibility criteria: Inclusion Criteria:

1. Male or female 18 years of age or older
2. Diagnosis of at least two episodes of recurrent pericarditis\*,
3. At least 1 day with pericarditis pain ≥4 on the 11-point Numerical Rating Scale (NRS) within prior 7 days
4. One of;

   1. C-Reactive Protein\*\* (CRP) level ≥1.0 mg/dL within prior 7 days OR
   2. Evidence of pericardial inflammation assessed by delayed pericardial hyperenhancement on cardiac magnetic resonance imaging (CMR)
5. Currently receiving non-steroidal anti-inflammatory drugs (NSAIDs) and/or colchicine and/or corticosteroids (in any combination) for treatment of pericarditis in stable doses
6. Male patients with partners of childbearing potential who have had a vasectomy or are willing to use double barrier contraception methods during the conduct of the study and for 2 months after the last dose of study drug.
7. Women of childbearing potential willing to use an acceptable method of contraception starting with study drug administration and for a minimum of 2 months after study completion. Otherwise, women must be postmenopausal (at least 1 y absence of vaginal bleeding or spotting and confirmed by follicle stimulating hormone \[FSH\] ≥40 mIU/mL \[or ≥ 40 IU/L\] if less than 2 y postmenopausal) or be surgically sterile.

   * Diagnosis of pericarditis according to the 2015 European Society of Cardiology (ESC) Guidelines for the Diagnosis and Management of Pericardial Diseases (Adler et al. 2015):

At least two of:

1. Pericarditic chest pain
2. Pericardial rub
3. New widespread ST-segment elevation or PR-segment depression according to electrocardiogram (ECG) findings
4. Pericardial effusion (new or worsening)

   * Conversion: 1 mg/dL CRP = 10 mg/L hs-CRP

Exclusion Criteria:

1. Diagnosis of pericarditis that is secondary to specific prohibited etiologies, including tuberculosis (TB); neoplastic, purulent, or radiation etiologies; post-thoracic blunt trauma (e.g., motor vehicle accident); myocarditis
2. Estimated glomerular filtration rate (eGFR) \<30 mL/min at screening
3. Elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 5 times the upper limit of normal (ULN) or ALT or AST \>3x ULN plus bilirubin \>2x ULN
4. Sepsis, defined as documented bacteremia at the time of screening or other documented active infection
5. Prior history of sustained ventricular arrhythmia
6. History of QT interval prolongation
7. QTc interval \> 500 msec
8. Current participation in any research study involving investigational drugs or device
9. Inability or unwillingness to give informed consent
10. Ongoing drug or alcohol abuse
11. On any cannabinoid during the past month
12. Women who are pregnant or breastfeeding
13. Current diagnosis of cancer, with the exception of non-melanoma skin cancer
14. Any factor, which would make it unlikely that the patient can comply with the study procedures
15. Showing suicidal tendency as per the Columbia Suicide Severity Rating Scale (C-SSRS), administered at screening
16. On digoxin and/or type 1 or 3 antiarrhythmics
17. On immunosuppressive therapy with any of the following:

    1. Rilonacept
    2. Anakinra
    3. Canakinumab
    4. Methotrexate
    5. Azathioprine
    6. Cyclosporine
    7. Intravenous immune globulin (IVIG)

Primary outcomes:
measure: 11-point NRS pain score
timeFrame: 8 weeks
Secondary outcomes:
measure: 11-point NRS pain score
timeFrame: 26 weeks
measure: Percentage of patients with normalized CRP levels
timeFrame: 8 weeks
measure: Percentage of patients with pericarditis recurrence during the extension period (EP)
timeFrame: 26 weeks
measure: Percentage of patients with normalized CRP levels
timeFrame: 26 weeks
measure: Time to normalized CRP levels
timeFrame: Over 26 weeks
measure: CRP change from baseline
timeFrame: 26 weeks
Other outcomes:
Locations:
city: Tucson
country: United States
facility: Pima Heart and Vascular Clinical Research
state: Arizona
city: Washington
country: United States
facility: MedStar Health Research Institute
state: District of Columbia
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Minneapolis
country: United States
facility: Minneapolis Heart Institute Foundation
state: Minnesota
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
city: Cleveland
country: United States
facility: Cleveland Clinic
state: Ohio
city: Burlington
country: United States
facility: University of Vermont Medical Center
state: Vermont
city: Richmond
country: United States
facility: Virginia Commonwealth University Health
state: Virginia
Study officials:
affiliation: The Cleveland Clinic
name: Allen Klein, MD
role: STUDY_CHAIR
References:
citation: Adler Y, Charron P, Imazio M, Badano L, Baron-Esquivias G, Bogaert J, Brucato A, Gueret P, Klingel K, Lionis C, Maisch B, Mayosi B, Pavie A, Ristic AD, Sabate Tenas M, Seferovic P, Swedberg K, Tomkowski W; ESC Scientific Document Group. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015 Nov 7;36(42):2921-2964. doi: 10.1093/eurheartj/ehv318. Epub 2015 Aug 29. No abstract available.
citation: Klein AL, Imazio M, Cremer P, Brucato A, Abbate A, Fang F, Insalaco A, LeWinter M, Lewis BS, Lin D, Luis SA, Nicholls SJ, Pano A, Wheeler A, Paolini JF; RHAPSODY Investigators. Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis. N Engl J Med. 2021 Jan 7;384(1):31-41. doi: 10.1056/NEJMoa2027892. Epub 2020 Nov 16.